Gene Therapy for Subjects With RPGR Mutation-associated X-linked Retinitis Pigmentosa

NCT05874310 · tracked via the Priya Life Science China tracker

Sponsor

Frontera Therapeutics

Phase

Phase EARLY_PHASE1

Started

2023-02-01

Last updated

2023-05-24

Condition(s) studied

X-Linked Retinitis Pigmentosa

Investigational drug(s) / intervention(s)

FT-002

FT-002: Comparison of different dosages of FT-002

Study summary

A clinical trial of gene therapy for patients with X-linked retinitis pigmentosa (XLRP).

Eligibility

Sex

MALE

Min age

8 Years

Max age

45 Years

Healthy volunteers

Inclusion Criteria: 1.Subjects that are willing and able to follow study procedures; 2.Males aged 8-45 years old at the time of signing the Informed Consent Form; 4.Subjects who are confirmed with variants of RPGR ; Exclusion Criteria: 1.Have other retinal degenerative diseases, such as retinal degeneration caused by other known Inherited retinal disease gene variants or previously received an gene therapy product.

Primary outcome measure(s)

Incidence of AEs — from FT-002 administration through up to 1 years
Number and proportion of Adverse Events

Trial sites (2)

Facility	City	Region	Status
Peking Union Medical College Hospital	Beijing	Beijing Municipality	Recruiting
Eye & ENT hospital of Fudan university	Shanghai	Shanghai Municipality	Recruiting

More Frontera Therapeutics trials in China

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy Recruiting

Gene Therapy for Diabetic Macular Edema Recruiting

Gene Therapy(FT-003) for Wet AMD Recruiting

Gene Therapy for DME Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05874310 on ClinicalTrials.gov ↗ ← All trials in China